Inotrem reports 'favorable' markers for septic shock candidate

Inotrem S.A. (Nancy, France) said nangibotide (LR12) was safe and led to "consistent trends in a more favorable evolution of biological and clinical activity markers" in a subgroup of patients with baseline soluble triggering receptor expressed on myeloid cells 1 (TREM1) levels above median in a Phase IIa trial to treat septic shock. Data were presented at the International Sepsis Forum in Bangkok. The double-blind, European trial enrolled 49 septic shock patients to receive placebo or nangibotide.

Inotrem plans to start a Phase IIb trial next year of nangibotide in the indication. Nangibotide, a TREM1 inhibitor, has PRIority MEdicines (PRIME) designation in the EU...